Feature | Stents Bioresorbable | September 04, 2015

Absorbable Stents Prove Non-Inferior to Metal in STEMI Study

Abbott's bioresorbable vascular scaffold performs similarly to gold-standard bare metal stent

ABSORB STEMI TROFI II trial, ESC 2015, bioresorbable vascular scaffold, BVS, STEMI patients

Image courtesy of Abbott Vascular

September 4, 2015 — A drug-eluting coronary stent made of absorbable material performed similarly to gold-standard metal among patients with an ST-segment elevation myocardial infarction (STEMI), according to results of the ABSORB STEMI TROFI II trial.

“This is the first randomized, controlled trial to compare the stent coverage between these two types of stents in the STEMI setting,” said senior investigator Patrick W Serruys, M.D., Ph.D., who presented the findings at the European Society of Cardiology (ESC) Congress 2015, with simultaneous publication in the European Heart Journal.

Unlike metallic stents which remain permanently in place, absorbable stents — also known as “bioresorbable vascular scaffolds” (BVS) — eventually biodegrade, restoring the natural physiology of coronary vessels – “a factor which may be more important in STEMI patients, who tend to have delayed arterial healing as compared to patients with stable coronary artery disease,” explained Serruys, from the International Centre for Circulatory Health, Imperial College, London.

The study included 191 STEMI patients (mean age 58.6 years) undergoing primary percutaneous coronary intervention at eight medical centers.

Patients were randomized to receive either the Abbott Vascular Absorb BVS (n=95) or a metallic stent (n=96), both types being “drug-eluting”, meaning coated in everolimus, a drug to reduce the risk of vessel reblockage.

The primary endpoint of the study was a six-month score assessing stent coverage and restenosis of the vessel using coronary optical coherence tomography (OCT) imaging.

Given the chosen criteria for non-inferiority, the score was similar (1.74 in the BVS arm and 2.80 in the metallic stent arm), indicating almost complete arterial healing in both groups and meeting the criteria for non-inferiority (P<0.001).

Clinical events measured as a composite of cardiac death, target vessel myocardial infarction (MI), or clinically-driven target lesion revascularization, were 1.1 percent in the BVS arm compared to 0 percent in the metallic stent arm (P=ns). There was one case of definite subacute thrombosis in the BVS arm.

“This trial provides the basis for further exploration in clinical outcomes trials,” noted Serruys.

The study was funded by Abbott, the European Cardiovascular Research Institute (ECRI) and Terumo Europe N.V.

Serruys is a member of the international advisory board of Abbott.

For more information: www.escardio.org

Related Content

Videos | Cath Lab| January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab| January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab| November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab| November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab| November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Three-Year Quality of Life Improvements Similar for PCI and CABG in Left Main Disease
News | Cath Lab| October 30, 2017
October 30, 2017 — New study results from the EXCEL trial comparing the quality of life (QoL) of patients with left m
Corindus Evaluates Incorporating HeartFlow Technology With CorPath GRX System
Technology | Cath Lab| October 26, 2017
Corindus Vascular Robotics Inc. announced that it will incorporate the HeartFlow FFRct (fractional flow reserve-...
Shockwave Medical Announces $35 Million in New Financing
News | Cath Lab| October 24, 2017
October 24, 2017 — Shockwave Medical reported $35 million in new financing, an extension of the company’s previously
Overlay Init